<DOC>
	<DOC>NCT01791725</DOC>
	<brief_summary>This is a prospective, randomized, double-blind, placebo-controlled, parallel-group, three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4 weeks. This study will enroll Down Syndrome patients 18 to 45 years of age (inclusive) without dementia.</brief_summary>
	<brief_title>A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>18 45 years of age Has an IQ of &gt; 40 (KBIT) Able and willing to have a brain MRI Symptoms of dementia or worsening cognition over the past year. Has a history of hepatitis B, hepatitis C, or HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>